Keratoconus and crosslinking: pharmacokinetic considerations

Bibliography

• Rabinowitz YS. Keratoconus. Surv Ophthalmol 1998;42:297–319
   PubMed Web of Science ®Google Scholar
• Krachmer JH, Feder RS, Belin MW. Keratoconus and related non-inflammatory corneal thinning disorders. Surv Ophthalmol 1984;28:293-322
   PubMed Web of Science ®Google Scholar
• Wagner H, Barr JT, Zadnik K. Collaborative longitudinal evaluation of keratoconus (CLEK) study: methods and findings to date. Cont Lens Anterior Eye 2007;30:223-32
   PubMedGoogle Scholar
• Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol 2003;135:620-7
   PubMed Web of Science ®Google Scholar
• Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg 2003;29:1780-5
   PubMed Web of Science ®Google Scholar
• Wollensak G. Crosslinking treatment of progressive keratoconus: new hope. Curr Opin Ophthalmol 2006;17:356-60
   PubMed Web of Science ®Google Scholar
• Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg 2008;34:796-801
   PubMed Web of Science ®Google Scholar
• Wollensak G. Corneal collagen crosslinking: new horizons. Expert Rev Ophthalmol 2010;5:201-15
   Google Scholar
• McCall AS, Kraft S, Edelhauser HF, et al. Mechanisms of corneal tissue cross-linking in response to treatment with topical riboflavin and long wavelength ultraviolet radiation (UVA). Invest Ophthalmol Vis Sci 2010;51:129-38
   PubMed Web of Science ®Google Scholar
• Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin crosslinking of the cornea. Cornea 2007;26:385-9
   PubMed Web of Science ®Google Scholar
• Kohlhaas M, Spoerl E, Schilde T, et al. Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light. J Cataract Refract Surg 2006;32:279-83
   PubMed Web of Science ®Google Scholar
• Wollensak G, Spoerl E, Wilsch M, Seiler T. Collagen fiber diameter in the rabbit cornea after collagen cross-linking by riboflavin/UVA. Cornea 2004;23:503-7
   PubMed Web of Science ®Google Scholar
• Wollensak G, Aurich H, Pham D-T, et al. Hydration behavior of porcine cornea crosslinked with riboflavin and ultraviolet A. J Cataract Refract Surg 2007;33:516-21
   PubMed Web of Science ®Google Scholar
• Caporossi A, Mazzotta C, Baiocchi S, Caporossi T. Longterm results of riboflavin ultraviolet A corneal collagen cross-linking for keratoconus in Italy: the Siena Eye Cross Study. Am J Ophthalmol 2010;149:585-93
   PubMed Web of Science ®Google Scholar
• Goldich Y, Marcovich AL, Barkana Y, et al. Clinical and corneal biomechanical changes after collagen cross-linking with riboflavin and UV irradiation in patients with progressive keratoconus: results after 2 years of follow-up. Cornea 2012;31:609-14
   PubMed Web of Science ®Google Scholar
• Mazzotta C, Traversi C, Baiocchi S, et al. Corneal healing after riboflavin ultraviolet-A collagen cross-linking determined by confocal laser scanning microscopy in vivo: early and late modifications. Am J Ophthalmol 2008;146:527-33
   PubMed Web of Science ®Google Scholar
• Koller T, Pajic B, Vinciguerra P, Seiler T. Flattening of the cornea after collagen crosslinking for keratoconus. J Cataract Refract Surg 2011;37:1488-92
   PubMed Web of Science ®Google Scholar
• Wittig-Silva C, Whiting M, Lamoureux E, et al. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg 2008;24:S720-5
   PubMed Web of Science ®Google Scholar
• Raiskup F, Spoerl E. Corneal cross-linking with hypo-osmolar riboflavin solution in thin keratoconic corneas. Am J Ophthalmol 2011;152:28-32
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Nubile M, Lanzini M, et al. Morphological modification of the cornea after standard and transepithelial corneal cross-linking as imaged by anterior segment optical coherence tomography and laser scanning in vivo confocal microscopy. Cornea 2013;32(6):855-61
   PubMed Web of Science ®Google Scholar
• Caporossi A, Baiocchi S, Mazzotta C, et al. Parasurgical therapy for keratoconus by riboflavin–ultraviolet type A rays induced cross-linking of corneal collagen preliminary refractive results in an Italian study. J Cataract Refract Surg 2006;32:837-45
   PubMed Web of Science ®Google Scholar
• Sawaguchi S, Twining SS, Yue BY, et al. Alpha 2 macroglobulin levels in normal human and keratoconus corneas. Invest Ophthalmol Vis Sci 1994;35:4008-14
   PubMed Web of Science ®Google Scholar
• Kenney MC, Nesburn AB, Burgeson RE, et al. Abnormalities of the extracellular matrix in keratoconus. Cornea 1997;16:345-51
   PubMed Web of Science ®Google Scholar
• Collier SA, Madigan MC, Penfold PL. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) and MMP-2 in normal and keratoconus corneas. Curr Eye Res 2000;21:662-8
   PubMed Web of Science ®Google Scholar
• Collier SA. Is the corneal degradation in keratoconus caused by matrixmetalloproteinases? Clin Experiment Ophthalmol 2001;29:340-4
   PubMed Web of Science ®Google Scholar
• Critchfield JW, Calandra AJ, Nesburn AB, Kenney C. Keratoconus. I. Biochemical studies of normal and keratoconus corneas. Exp Eye Res 1988;46:953-63
   PubMed Web of Science ®Google Scholar
• Maatta M, Vaisanen T, Vaisanen MR, et al. Altered expression of type XIII collagen in keratoconus and scarred human cornea increased expression in scarred cornea is associated with myofibroblast transformation. Cornea 2006;25:448-53
   PubMed Web of Science ®Google Scholar
• Romero-Jimenez M, Santodomingo-Rubido J, Wolffsohn JS. Keratoconus: a review. Cont Lens Anterior Eye 2010;33:157-66
   PubMed Web of Science ®Google Scholar
• Yue BY, Sugar J, Benveniste K. Heterogeneity in keratoconus: possible biochemical basis. Proc Soc Exp Biol Med 1985;175:336-41
   Web of Science ®Google Scholar
• Kao WW, Vergnes JP, Ebert J, et al. Increased collagenase and gelatinase activities in keratoconus. Biochem Biophys Res Commun 1982;107:929-36
   PubMed Web of Science ®Google Scholar
• Abalain JH, Dossou H, Colin J, Floch HH. Levels of collagen degradation products (telopeptides) in the tear film of patients with keratoconus. Cornea 2000;19:474-6
   PubMed Web of Science ®Google Scholar
• Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54
   PubMed Web of Science ®Google Scholar
• Fini ME, Yue BY, Sugar J. Collagenolytic/gelatinolytic metalloproteinases in normal human and keratoconus corneas. Curr Eye Res 1992;9:849-62
   Web of Science ®Google Scholar
• Brown D, Chwa MM, Opbroek A, Kenney MC. Keratoconus corneas: increased gelatinolytic activity appears after modification of inhibitors. Curr Eye Res 1993;12:571-81
   PubMed Web of Science ®Google Scholar
• Kenney MC, Chwa M, Opbroek AJ, et al. Increased gelatinolytic activity in keratoconus keratocyte cultures. A correlation to an altered matrix metalloproteinase-2/tissue inhibitor of metalloproteinase ratio. Cornea 1994;13:114-24
   PubMed Web of Science ®Google Scholar
• Brown D, Chwa M, Escobar M, Kenny MC. Characterisation of the major matrix degrading metalloproteinase of human corneal stroma. Evidence for an enzyme/inhibitor complex. Exp Eye Res 1991;52:5-16
   PubMed Web of Science ®Google Scholar
• Kenney MC, Chwa M, Alba A, et al. Localization of TIMP-1, TIMP-2, TIMP-3, gelatinase A and gelatinase B in pathological human corneas. Curr Eye Res 1998;17:238-46
   PubMed Web of Science ®Google Scholar
• Lema I, Duran JA. Inflammatory molecules in the tears of patients with keratoconus. Ophthalmology 2005;112:654-9
   PubMed Web of Science ®Google Scholar
• Mackiewicz Z, Maatta M, Stenman M, et al. Collagenolytic proteinases in keratoconus. Cornea 2006;25:603-10
   PubMed Web of Science ®Google Scholar
• Sorsa T, Salo T, Koivunen E, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 1997;272:21067-74
   PubMed Web of Science ®Google Scholar
• Ortak H, Sogüt E, Taso U, et al. The relation between keratoconus and plasma levels of MMP-2, zinc, and SOD. Cornea 2012;31:1048-51
   PubMed Web of Science ®Google Scholar
• Whitelock RB, Fukuchi T, Zhou L, et al. Cathepsin G, acid phosphatase, and alpha 1-proteinase inhibitor messenger RNA levels in keratoconus corneas. Invest Ophthalmol Vis Sci 1997;38:529-34
   PubMed Web of Science ®Google Scholar
• Zhou L, Sawaguchi S, Twining SS, et al. Expression of degradative enzymes and protease inhibitors in corneas with keratoconus. Invest Ophthalmol Vis Sci 1998;39:1117-24
   PubMed Web of Science ®Google Scholar
• Bonini S, Lambiase A, Juhas T, et al. Inflammatory immune-associated diseases of the cornea. In: Ben Ezra D, editor. Ocular inflammation: basic and clinical concepts. Martin Dunitz; London: 1999. p. 151-68
   Google Scholar
• Planck SR, Huang XN, Robertson JE, et al. Cytokine mRNA levels in rat ocular tissues following systemic endotoxin treatment. Invest Ophthalmol Vis Sci 1994;35:924-30
   PubMed Web of Science ®Google Scholar
• Lema I, Sobrino T, Duran JA, et al. Subclinical keratoconus and inflammatory molecules from tears. Br J Ophthalmol 2009;93:820-4
   PubMed Web of Science ®Google Scholar
• Sugaya S, Sakimoto T, Shoji J, Sawa M. Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface. Jpn J Ophthalmol 2011;55:277-82
   PubMed Web of Science ®Google Scholar
• Ebihara N, Matsuda A, Nakamura S, et al. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing. Invest Ophthalmol Vis Sci 2011;52:8549-57
   PubMed Web of Science ®Google Scholar
• Jones SA, Horiuchi S, Topley N, et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001;15:43-58
   PubMed Web of Science ®Google Scholar
• Drucker C, Gewiese J, Malchow S, et al. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun 2010;34:29-37
   Google Scholar
• Knupfer H, Preiss R. sIL-6R: more than an agonist? Immunol Cell Biol 2008;86:87-91
   PubMed Web of Science ®Google Scholar
• Izumi-Nagai K, Nagai N, Ozawa Y, et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol 2007;170:2149-58
   PubMed Web of Science ®Google Scholar
• Simon D, Denniston AK, Tomlins PJ, et al. Soluble gp130, an antagonist of IL-6 transsignaling, is elevated in uveitis aqueous humor. Invest Ophthalmol Vis Sci 2008;49:3988-91
   PubMed Web of Science ®Google Scholar
• Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009;28:1023-7
   PubMed Web of Science ®Google Scholar
• Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea 2007;26:431-7
   PubMed Web of Science ®Google Scholar
• Xue ML, Wakefield D, Willcox MD, et al. Regulation of MMPs and TIMPs by IL-1beta during corneal ulceration and infection. Invest Ophthalmol Vis Sci 2003;44:2020-5
   PubMed Web of Science ®Google Scholar
• Li DQ, Lokeshwar BL, Solomon A, et al. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res 2001;73:449-59
   PubMed Web of Science ®Google Scholar
• Kim HS, Shang T, Chen Z, et al. TGF-beta1 stimulates production of gelatinase (MMP-9), collagenases (MMP-1, -13) and stromelysins (MMP-3, -10, -11) by human corneal epithelial cells. Exp Eye Res 2004;79:263-74
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Hsu YL, Wu KY, et al. Heat effect induces production of inflammatory cytokines through heat shock protein 90 pathway in cornea cells. Curr Eye Res 2013;38:464-71
   PubMed Web of Science ®Google Scholar
• Mazzotta C, Balestrazzi A, Traversi C, et al. Treatment of progressive keratoconus by riboflavin-UVA–induced cross-linking of corneal collagen ultrastructural analysis by Heidelberg retinal tomograph II in vivo confocal microscopy in humans. Cornea 2007;26:390-7
   PubMed Web of Science ®Google Scholar
• Kymionis GD, Grentzelos MA, Plaka AD, et al. Evaluation of the corneal collagen cross-linking demarcation line profile using anterior segment optical coherence tomography. Cornea 2013;32(7):907-10
   PubMed Web of Science ®Google Scholar
• Doors M, Tahzib NG, Eggink FA, et al. Use of anterior segment optical coherence tomography to study corneal changes after collagen cross-linking. Am J Ophthalmol 2009;148:844-51
   PubMed Web of Science ®Google Scholar
• Grobe GM, Reichl S. Examining the suitability of riboflavin/UVA treatment for strengthening the stromal bioequivalent of a human cornea construct. Curr Eye Res 2011;36:217-31
   PubMed Web of Science ®Google Scholar
• Sharma A, Nottage JM, Mirchia K, et al. Persistent corneal edema after collagen cross-linking for keratoconus. Am J Ophthalmol 2012;154:922-6
   PubMed Web of Science ®Google Scholar
• Lange C, Böhringer D, Reinhard T. Corneal endothelial loss after crosslinking with riboflavin and ultraviolet-A. Arch Clin Exp Ophthalmol 2012;250:1689-91
   PubMed Web of Science ®Google Scholar
• Lim LS, Beuerman R, Lim L, Tan DTH. Late-onset deep stromal scarring after riboflavin–UV-A corneal collagen cross-linking for mild keratoconus. Arch Ophthalmol 2011;129:360-2
   PubMed Web of Science ®Google Scholar
• Koppen C, Vryghem JC, Gobin L, Tassignon MJ. Keratitis and corneal scarring after UVA/riboflavin cross-linking for keratoconus. J Refract Surg 2009;25:S819-23
   PubMed Web of Science ®Google Scholar
• Ghanem RC, Netto MV, Ghanem VC, et al. Peripheral sterile corneal ring infiltrate after riboflavin–UVA collagen cross-linking in keratoconus. Cornea 2012;31:702-5
   PubMed Web of Science ®Google Scholar
• Podskochy A, Fagerholm P. Repeated UVR exposures cause keratocyte resistance to apoptosis and hyaluronan accumulation in the rabbit cornea. Acta Ophthalmol Scand 2001;79:603-8
   PubMedGoogle Scholar
• Wollensak G, Mazzotta C, Kalinski T, Sel S. Limbal and conjunctival epithelium after corneal cross-linking using riboflavin and UVA. Cornea 2011;30:1448-54
   PubMed Web of Science ®Google Scholar
• Matalia H, Shetty R, Dhamodaran K, et al. Potential apoptotic effect of ultraviolet-A irradiation during cross-linking: a study on ex vivo cultivated limbal epithelial cells. Br J Ophthalmol 2012;96:1339-45
   PubMed Web of Science ®Google Scholar
• Thorsrud A, Nicolaissen B, Drolsum L. Corneal collagen crosslinking in vitro: inhibited regeneration of human limbal epithelial cells after riboflavin-ultraviolet-A exposure. J Cataract Refract Surg 2012;38:1072-6
   PubMed Web of Science ®Google Scholar
• Raiskup F, Hoyer A, Spoerl E. Permanent corneal haze after riboflavin-UVA-induced cross-linking in keratoconus. J Refract Surg 2009;25:S824-8
   PubMed Web of Science ®Google Scholar
• Hafezi F, Mrochen M, Iseli HP, et al. Collagen crosslinking with ultraviolet-A and hypoosmolar riboflavin solution in thin corneas. J Cataract Refract Surg 2009;35:621-4
   PubMed Web of Science ®Google Scholar
• Wollensak G, Aurich H, Wirbelauer C, Pham D-T. Potential use of riboflavin/UVA cross-linking in bullous keratopathy. Ophthalmic Res 2009;41:114-17
   PubMed Web of Science ®Google Scholar
• Vetter JM, Brueckner S, Tubic-Grozdanis M, et al. Modulation of central corneal thickness by various riboflavin eyedrop compositions in porcine corneas. J Cataract Refract Surg 2012;38:525-32
   PubMed Web of Science ®Google Scholar
• Kaya V, Utine CA, Yılmaz OF. Intraoperative corneal thickness measurements during corneal collagen cross-linking with hypoosmolar riboflavin solution in thin corneas. Cornea 2012;31:486-90
   PubMed Web of Science ®Google Scholar
• Hafezi F. Limitation of collagen cross-linking with hypoosmolar riboflavin solution: failure in an extremely thin cornea. Cornea 2011;30:917-19
   PubMed Web of Science ®Google Scholar
• Burgalassi S, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicol Lett 2001;122:1-8
   PubMed Web of Science ®Google Scholar
• Kusano M, Uematsu M, Kumagami T, et al. Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo. Cornea 2010;29:80-5
   PubMed Web of Science ®Google Scholar
• Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007;48:4123-8
   PubMed Web of Science ®Google Scholar
• Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. J Clin Exp Ophthalmol 2004;32:180-4
   Google Scholar
• Raiskup F, Pinelli R, Spoerl E. Riboflavin osmolar modification for transepithelial corneal cross-linking. Curr Eye Res 2012;37:234-8
   PubMed Web of Science ®Google Scholar
• Kissner A, Spoerl E, Jung R, et al. Pharmacological modification of the epithelial permeability by benzalkonium chloride in UVA/riboflavin corneal collagen cross-linking. Curr Eye Res 2010;35:715-21
   PubMed Web of Science ®Google Scholar
• Kymionis GD, Portaliou DM, Diakonis VF, et al. Corneal collagen cross-linking with riboflavin and ultraviolet-A irradiation in patients with thin corneas. Am J Ophthalmol 2012;153:24-8
   PubMed Web of Science ®Google Scholar
• Kymionis GD, Diakonis VF, Kalyvianaki M, et al. One-year follow-up of corneal confocal microscopy after corneal cross-linking in patients with post laser in situ keratosmileusis ectasia and keratoconus. Am J Ophthalmol 2009;147:774-8
   PubMed Web of Science ®Google Scholar
• Mazzotta C, Baiocchi S, Caporossi T, et al. Riboflavin 0.1% (VibeX) for the treatment of keratoconus. Expert Opin Orphan Drugs 2013;1:235-40
   Web of Science ®Google Scholar
• Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1997;5:175-85
   Google Scholar